FOR IMMEDIATE RELEASE CONTACT:
NFL-92 10/21/04

Matt Hill, NFL, 212-450-2080
Hillm@NFL.com

Howard Clabo, FedEx, 901-434-7786
Howard.Clabo@fedex.com

NFL.COM VOTERS SELECT
VIKINGS QB DAUNTE CULPEPPER & BRONCOS RB REUBEN DROUGHNS
AS WEEK 6 FEDEX AIR & GROUND NFL PLAYERS OF THE WEEK

Quarterback DAUNTE CULPEPPER of the Minnesota Vikings and running back REUBEN DROUGHNS of the Denver Broncos are the FedEx Air & Ground NFL Players of the Week for games played on October 17-18, the NFL announced today.

Culpepper threw for 425 yards and five touchdowns, completing 26 of 37 pass attempts for a 125.6 passer rating in the Vikings’ 38-31 win over the New Orleans Saints. His 425 passing yards were a career high, and he set an NFL record by throwing five touchdown passes for the third time in one season.

Droughns carried 38 times for 176 yards and one touchdown in the Broncos’ 31-3 victory over the AFC West-rival Oakland Raiders. This was the second game in a row Droughns ran for more than 175 yards.

Culpepper and Droughns were selected from among finalists in the air and ground categories through 49,834 fan votes. The other FedEx Express NFL Player of the Week finalists were quarterbacks JEFF GARCIA of the Cleveland Browns and BYRON LEFTWICH of the Jacksonville Jaguars, while running backs CURTIS MARTIN of the New York Jets and CLINTON PORTIS of the Washington Redskins were the other finalists for FedEx Ground NFL Player of the Week.

Fans voted for more than their favorite players. The weekly FedEx Air & Ground NFL Players of the Week Awards are also a win for the local community. Along with the player awards, FedEx is awarding Fairview University Children's Hospital and the Children's Hospital Foundation, the Children’s Hospital in each winning market, a check for $5,000.

The children’s hospitals in the two season-long winner’s markets, announced at this year’s Super Bowl, will be awarded $25,000 each. That means that FedEx will deliver nearly $250,000 to local children’s hospitals around the country in recognition of the FedEx Air & Ground NFL Players of the Week Award winners.

FedEx, the premier global provider of transportation, e-commerce and supply-chain management services, is the Official Delivery Service Sponsor of the NFL, Super Bowl and Pro Bowl. Through the weekly FedEx Air and Ground awards, FedEx recognizes those NFL players who represent the same speed, precision and teamwork that their customers have come to expect from the full range of FedEx air, ground, freight and international shipping services.

 

2004 FEDEX AIR & GROUND NFL PLAYERS OF THE WEEK

  EXPRESS (AIR) Charity GROUND Charity
Wk 1 Donovan McNabb, Phi. Children's Hospital of Philadelphia Curtis Martin, NYJ Bristol-Myers Squibb Children's Hospital
Wk 2 Aaron Brooks, NO Children's Hospital of New Orleans DeShaun Foster, Car. Children's Hospital at Carolinas Medical Center
Wk 3 Peyton Manning, Ind. Riley Hospital for Children Jamal Lewis, Bal. Union Memorial Hospital
Wk 4 Byron Leftwich, Jac. Wolfson Children's Hospital Tiki Barber, NYG Tomorrows Children’s Fund
Wk 5 Daunte Culpepper, Min. Fairview University Children's Hospital Chris Brown, Ten. Neo-Natal Intensive Care Unit at Baptist Hospital
Wk 6 Daunte Culpepper, Min. Fairview University Children's Hospital Reuben Droughns, Den. Children's Hospital Foundation

 

FOR IMMEDIATE RELEASE CONTACT:
NFL-93 10/21/04

MATT HILL, NFL, 212-450-2080
Hillm@NFL.com

DAVE DECECCO, PEPSI-COLA, 914-253-2655
David.DeCecco@Pepsi.com

NFL.COM VOTERS SELECT STEELERS QB BEN ROETHLISBERGER
AS PEPSI NFL ROOKIE OF THE WEEK FOR FOURTH WEEK IN A ROW

Voters on NFL.com have made their choice. Quarterback BEN ROETHLISBERGER of the Pittsburgh Steelers is the PEPSI NFL ROOKIE OF THE WEEK for games played on October 17-18, the NFL announced today.

Roethlisberger, who was also named Pepsi Rookie of the Week in Weeks 3, 4 and 5, completed 21 of 25 passes for 193 yards and two touchdowns in the Steelers’ 24-20 victory over the Dallas Cowboys. He improved to 4-0 as a starter, throwing touchdown passes of five and seven yards and finishing with a passer rating of 125.5.

More than 78,851 fans voted this week on NFL.com. Roethlisberger was selected from among five finalists. The other finalists were wide receiver MICHAEL CLAYTON of the Tampa Bay Buccaneers, running back MEWELDE MOORE of the Minnesota Vikings, safety SEAN TAYLOR of the Washington Redskins and linebacker JONATHAN VILMA of the New York Jets.

After the regular season, five players will be nominated for Pepsi NFL Rookie of the Year honors. Fans can vote for the winner on NFL.com throughout the month of January. The winner will be announced at a press conference at Super Bowl XXXIX in Jacksonville.

This is Pepsi’s third year as the official soft drink sponsor of the NFL.

2004 PEPSI NFL ROOKIE OF THE WEEK

   
Wk 1 S Erik Coleman, NY Jets (Washington State)
Wk 2 WR Roy Williams, Detroit Lions (Texas)
Wk 3 QB Ben Roethlisberger, Pittsburgh Steelers (Miami, OH)
Wk 4 QB Ben Roethlisberger, Pittsburgh Steelers (Miami, OH)
Wk 5 QB Ben Roethlisberger, Pittsburgh Steelers (Miami, OH)
Wk 6 QB Ben Roethlisberger, Pittsburgh Steelers (Miami, OH)

 

 

Contact: Contact:

Seth Rubin                                                                                           Matt Hill
Alan Taylor Communications                                                              National Football League
212-714-1280 ext.                                                                                353 212-450-2080
seth@alantaylor.com                                                                               hillm@nfl.com

KIMO VON OELHOFFEN’S FUMBLE RECOVERY NAMED THE WEEK SIX "LEVITRAâ (vardenafil HCI) PLAY OF WEEK"

NEW YORK—OCTOBER 21, 2004 – Pittsburgh Steelers defensive tackle Kimo von Oelhoffen’s 21-yard fumble recovery to set up the game-winning touchdown against the Dallas Cowboys has been voted the "LEVITRAâ (vardenafil HCI) PLAY OF THE WEEK" for NFL games played October 17-18.

Von Oelhoffen’s fumble recovery is now eligible to be selected as the "LEVITRAâ PLAY OF THE YEAR," awarded this February at Super Bowl XXXIX in Jacksonville, Florida. The "LEVITRAâ PLAY OF THE WEEK," which is voted on by fans each week throughout the NFL season from Tuesday at noon ET to Thursday at noon ET on NFL.com, is presented each Thursday and recognizes the single most exciting play that week.

Fans who vote at NFL.com each week can also enter for their chance to win a three-day/two-night trip for two to Jacksonville, Florida to attend Super Bowl XXXIX on February 6, 2005, including round-trip airfare and hotel accommodations.

With his team trailing by three late in the fourth quarter, von Oelhoffen scooped up a Cowboys’ fumble and rumbled 21 yards to set up the eventual game-winning touchdown. On the play Steelers linebacker James Farrior rushed through the offensive line and knocked the ball loose before von Oelhoffen recovered it. With the 24-20 victory, the Steelers improved to 4-1.

Von Oelhoffen’s fumble recovery edged out Cleveland Browns wide receiver Andre Davis’ 99-yard touchdown reception from quarterback Jeff Garcia against the Cincinnati Bengals in fan voting on NFL.com. For details and video of this week’s nominees and the results of fan voting, please visit www.NFL.com/playoftheweek .

In July 2003, Bayer Pharmaceutical Corporation (Bayer) & GlaxoSmithKline(GSK), co-marketers of LEVITRA (vardenafil HCI), a prescription medicine that is used to treat erectile dysfunction (ED), announced their groundbreaking sponsorship of the NFL.

2004 LEVITRAâ PLAY OF THE WEEK Winners

Week Player Play Description
1 Donovan McNabb, Philadelphia Three-yard TD pass to Terrell Owens against the Giants
2 Roy Williams, Detroit 14-yard TD reception from Joey Harrington against the Texans
3 Joe Horn, New Orleans Nine-yard TD reception from Aaron Brooks against the Rams
4 Troy Polamalu, Pittsburgh 26-yard interception return for a touchdown against the Bengals
5 Brandon Lloyd, San Francisco 23-yard TD reception from Tim Rattay against the Cardinals
6 Kimo von Oelhoffen, Pittsburgh 21-yard fumble recovery against the Cowboys

About LEVITRA

LEVITRA is a prescription medicine that is used to treat erectile dysfunction (ED). Men taking nitrate drugs, often used to control chest pain (also known as angina), should not take LEVITRA. Men who use alpha blockers, sometimes prescribed for high blood pressure or prostate problems, also should not take LEVITRA. Such combinations could cause blood pressure to drop to an unsafe level.

You should not take LEVITRA if your doctor determines that sexual activity poses a health risk for you. Men who experience an erection for more than four hours should seek immediate medical attention. LEVITRA does not protect against sexually transmitted diseases.

The starting dose of LEVITRA is 10 mg taken no more than once per day. Your doctor will decide the dose that is right for you. In patients taking certain medications such as ritonavir, indinavir, ketoconazole, itraconazole, and erythromycin, lower doses of LEVITRA are recommended, and time between doses of LEVITRA may need to be extended.

In clinical trials, the most commonly reported side effects were headache, flushing, and stuffy or runny nose. LEVITRA is available in 2.5-mg, 5-mg, 10-mg, and 20-mg tablets.

About Erectile Dysfunction

The consistent or recurrent inability of a man to attain and/or maintain a penile erection sufficient for sexual performance1 – is a common health condition among men that is largely untreated. It is estimated that some degree of ED affects more than one half of all men over the age of 402– 152 million men worldwide3 and 30 million men in the United States alone.4

Despite the high prevalence of sexual problems, nine out of 10 men in the U.S. have not yet sought treatment from a physician.5

1. Jardin A, Wagner G, Khoury S, et al. Recommendations of the 1st International Consultation on Erectile Dysfunction. Co-sponsored by the World Health Organization (WHO), International Consultation on Urological Diseases (ICUD) and Societe Internationale d’Urologie (SIU) and held July 1-3, 1999, Paris. 2000, p. 713.

2. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.

3. Aytac IA, McKinlay JB, Krane RI. The likely worldwide increase of erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-56

4. National Institutes of Health, Consensus Development Conference Statement, December 7-9, 1992. Online data: http://odp.od.nih.gov/consensus/cons/091/091_statement.htm. (accessed 8/26/02).

5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-544.

About Bayer Pharmaceuticals Corporation
Bayer Pharmaceuticals Corporation (www.bayerpharma.com) is part of the worldwide operations of Bayer HealthCare AG, a subgroup of Bayer AG. Bayer HealthCare, with sales of approximately 8.9 billion Euro in 2003, is one of the world’s leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics Professional Testing Systems and Diagnostics Self Testing Systems and Pharmaceuticals. 34,600 people are employed by Bayer HealthCare worldwide.

Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.

Forward Looking Statement

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including its Form 20-F). Bayer assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

About GSK

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

For more information about LEVITRA, please visit www.LEVITRA.com.